Cargando…

TUDCA as an autophagic modulator of ATTR V30M Amyloidosis

Detalles Bibliográficos
Autores principales:	Teixeira, Cristina, Saraiva, Maria João
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642117/ http://dx.doi.org/10.1186/1750-1172-10-S1-P10

Ejemplares similares

The role of complement in ATTR amyloidosis: a new therapeutic avenue?
por: Panayiotou, Elena, et al.
Publicado: (2015)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses
por: Adams, David, et al.
Publicado: (2015)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)
por: Adams, David, et al.
Publicado: (2015)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Unravelling the epidemiology of late-onset and asymptomatic carriers of FAP ATTR V30M in a Portuguese population
por: Lemos, Carolina, et al.
Publicado: (2015)

Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Cellular environment of TTR deposits in an animal model of ATTR—Cardiomyopathy
por: Teixeira, Cristina, et al.
Publicado: (2023)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy
por: Eliahou, Ludivine, et al.
Publicado: (2015)

Comparison of MIBG and Diphosphonate scintigraphy in cardiac involvement of aTTR-FAP
por: Chequer, Renata, et al.
Publicado: (2015)

The Expression of Chemokines Is Downregulated in a Pre-Clinical Model of TTR V30M Amyloidosis
por: Moreira, João, et al.
Publicado: (2021)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Allele Specific Expression of the Transthyretin Gene in Swedish Patients with Hereditary Transthyretin Amyloidosis (ATTR V30M) Is Similar between the Two Alleles
por: Norgren, Nina, et al.
Publicado: (2012)

Neuroprotection of Anakinra on peripheral nerve neurodegeneration in single and combination protocols with TTR siRNA in a transgenic mouse model for human V30M transthyretin
por: Saraiva, Maria João, et al.
Publicado: (2015)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases
por: Beirão, João Melo, et al.
Publicado: (2015)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
por: Fontana , Marianna, et al.
Publicado: (2014)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Imaging cardiac ATTR amyloid
por: Hawkins, Philip N
Publicado: (2015)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis
por: Fritschka, Max, et al.
Publicado: (2017)

Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy
por: Panayiotou, E., et al.
Publicado: (2016)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness
por: Nativi-Nicolau, Jose N., et al.
Publicado: (2021)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Tauroursodeoxycholic Acid (TUDCA)—Lipid Interactions and Antioxidant Properties of TUDCA Studied in Model of Photoreceptor Membranes
por: Sabat, Michał J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4jt7r95nne9miabs7ouvnae05h